Short Interest in RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Rises By 618.4%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 1,444 shares, a growth of 618.4% from the July 15th total of 201 shares. Based on an average daily trading volume, of 3,592 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

RCN Pareto Strategic Allocation ETF Stock Performance

Shares of PRTO remained flat at $28.39 during trading hours on Thursday. The stock had a trading volume of 7 shares. The stock has a market capitalization of $629.66 million, a P/E ratio of -29.57 and a beta of 0.60. RCN Pareto Strategic Allocation ETF has a 1 year low of $24.68 and a 1 year high of $28.39.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.